2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
July 12, 2018Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and HaemostasisJuly 10, 2018Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational ResearchJune 25, 2018Catalyst Biosciences Joins the Russell 2000® IndexJune 19, 2018Catalyst Biosciences to Present at the JMP Securities 2018 Life Sciences ConferenceJune 18, 2018Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia BMay 10, 2018Catalyst Biosciences Announces Oral Presentation at the World Federation of Hemophilia 2018 World CongressMay 09, 2018Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with InhibitorsMay 03, 2018Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate UpdateApril 23, 2018Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual MeetingApril 12, 2018Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia BMarch 26, 2018Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) AssetMarch 19, 2018Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare ConferenceMarch 07, 2018Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care ConferenceMarch 05, 2018Catalyst Biosciences Announces the Calling of Remaining Warrants and Conversion of Remaining Series A Preferred Shares Issued April 12, 2017March 01, 2018Catalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results and Provides Corporate UpdateFebruary 26, 2018Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679dFebruary 15, 2018Catalyst Biosciences Announces Closing of Public Offering of Common StockFebruary 13, 2018Catalyst Biosciences Announces Pricing of Public Offering of Common StockFebruary 12, 2018Catalyst Biosciences Announces Proposed Public Offering of Common StockFebruary 09, 2018Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia BJanuary 31, 2018Catalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHADJanuary 04, 2018Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors